Literature DB >> 9218428

The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.

E L Saenko1, D Scandella.   

Abstract

A binding site for von Willebrand factor (vWf) was previously localized to the carboxyl terminus of the C2 domain of the light chain (LCh) of factor VIII (fVIII). The acidic region of the LCh, residues 1649-1689, also controls fVIII.vWf binding by an unknown mechanism. Although anti-acidic region monoclonal antibodies prevent formation of the fVIII.vWf complex, the direct involvement of the acidic region in this binding has not been demonstrated. By limited proteolysis of LCh with Staphylococcus aureus V8 protease, we prepared 14- and 63-kDa LCh fragments, which begin with fVIII residues 1672 and 1795, respectively. Using surface plasmon resonance to measure binding interactions, we demonstrated that the 14-kDa fragment binds to vWf, but its affinity for vWf (Kd 72 nM) was 19-fold lower than that of LCh. This was not due to an altered conformation of the acidic region within the 14-kDa fragment, since its affinity for an anti-acidic region monoclonal antibody was similar to that of LCh. All LCh derivatives lacking the acidic region (thrombin-cleaved LCh, recombinant C2, and 63-kDa fragment) had also greatly reduced affinities for vWf (Kd 564-660 nM) compared with LCh (Kd 3.8 nM). In addition, the similar affinities of these derivatives for vWf indicated that apart from its acidic region, the LCh contains no vWf binding site other than the one within C2. The reduced affinities of the LCh derivatives lacking the acidic region for monoclonal antibody NMC-VIII/5 (epitope, C2 residues 2170-2327) indicated that removal of the acidic region leads to a conformational change within C2. This change is likely to affect the conformation of the vWf binding site in C2, which overlaps the epitope of NMC-VIII/5; therefore, the acidic region also appears to be required to maintain the optimal conformation of this vWf binding site. Our results demonstrate that the acidic region and the C2 domain are both directly involved in forming a high affinity binding site for vWf.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218428     DOI: 10.1074/jbc.272.29.18007

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII.

Authors:  Andrew Yee; Austin N Oleskie; Anne M Dosey; Colin A Kretz; Robert D Gildersleeve; Somnath Dutta; Min Su; David Ginsburg; Georgios Skiniotis
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

3.  Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.

Authors:  Vivek S Purohit; Karthik Ramani; Rita Sarkar; Haig H Kazazian; Sathyamangalam V Balasubramanian
Journal:  J Biol Chem       Date:  2005-02-23       Impact factor: 5.157

4.  Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Authors:  Y Dargaud; A Pavlova; S Lacroix-Desmazes; K Fischer; M Soucie; S Claeyssens; D W Scott; R d'Oiron; G Lavigne-Lissalde; G Kenet; C Escuriola Ettingshausen; A Borel-Derlon; T Lambert; G Pasta; C Négrier
Journal:  Haemophilia       Date:  2016-01       Impact factor: 4.287

5.  Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.

Authors:  Lydia Castro-Núñez; Esther Bloem; Mariëtte G Boon-Spijker; Carmen van der Zwaan; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-11-20       Impact factor: 5.157

Review 6.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

7.  The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.

Authors:  Xianchi Dong; Nina C Leksa; Ekta Seth Chhabra; Joseph W Arndt; Qi Lu; Kevin E Knockenhauer; Robert T Peters; Timothy A Springer
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

8.  Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Authors:  Wojciech Jankowski; Yara Park; Joseph McGill; Eugene Maraskovsky; Marco Hofmann; Vincent P Diego; Bernadette W Luu; Tom E Howard; Roberta Kellerman; Nigel S Key; Zuben E Sauna
Journal:  Blood Adv       Date:  2019-05-14

9.  Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Authors:  S L Meeks; J F Healey; E T Parker; R T Barrow; P Lollar
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

Review 10.  Blood coagulation factor VIII: An overview.

Authors:  G M Bhopale; R K Nanda
Journal:  J Biosci       Date:  2003-12       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.